课题基金 / 基金详情

小热休克蛋白8经NF-κB通路对SOD1突变肌萎缩侧索硬化的保护机制研究

批准号:
82071434
项目类别:
面上项目
资助金额:
55.0 万元
负责人:
牛琦
依托单位:
学科分类:
神经退行性变及相关疾病
结题年份:
2024
批准年份:
2020
项目状态:
已结题
项目参与者:
牛琦

项目摘要

结项摘要

相似基金

相关文献

中文摘要
小热休克蛋白8(HSPB8)作为一种分子伴侣,具有促进错误折叠蛋白的自噬清除作用,对MN可能有保护作用,但是在ALS中具体机制不清。SOD1基因是最常见的ALS致病基因之一,我们用前期报道的SOD1G41D与SOD1G41S两个临床表现差异显著的家系,制备患者来源的iPSC细胞系,并用CRISPR/Cas9定点修复突变,将修复前后的iPSC分别定向诱导分化为SPMN、UMN、星形胶质及小胶质细胞,将MNs和胶质细胞分组进行混合培养,通过调控NF-κB通路,观察HSPB8在MNs中和各培养体系中表达变化,观察突变SOD1蛋白表达以及聚集,LC3-Ⅱ/Ⅰ比值,自噬等指标;并在动物模型上进行验证。本项目通过研究HSPB8经NF-κB通路调控对MNs功能的影响,揭示HSPB8对MNs的保护机制,提供HSPB8神经保护作用的新证据,为ALS治疗靶点提供新理论依据。
英文摘要
The abnormal accumulation of misfolded proteins in motor neurons (MN) may be one of the common pathological manifestations of ALS. As a molecular chaperone, small heat shock protein 8 (HspB8) can prevent the abnormal aggregation of misfolded protein and promote its autophagy clearance. HspB8 can be expressed in MN and regulated by nuclear transcription factor NF-κB, but its specific role in ALS is not clear. SOD1 gene is the most common pathogenic gene of familial ALS and we have reported two families of G41D/S with obvious difference in clinical manifestations which were used to prepare iPSC cell lines, and CRISPR/cas9 site-specific repair mutation was used to induce and differentiate iPSC before and after repair into SPMN, UMN, astrocytes and microglia. They were divided into groups for mixed culture. By up-regulation or down-regulation of NF-κB pathway, the changes of HspB8 expression in MN and mixed culture system of each group were observed. The changes of MN expression and aggregation of SOD1 protein were detected, and the LC3-Ⅱ/Ⅰ ratio was measured, the results demonstrate the effects of glial cells on HspB8 expression in neurons, and further we verify in animal model. By observing the regulatory mechanism of NF-κB pathway on HspB8 in MNs, this project reveals the protective mechanism of HspB8 on MNs, which can provide new evidence for neuroprotection of HspB8 and provide theoretical basis for the therapeutic target of ALS.
肌萎缩侧索硬化症(ALS)是进行性致死性神经系统变性病,致病机制复杂,尚无有效治疗方法,是国内外研究的热点和难点。错误折叠蛋白的异常聚集是ALS共同的病理变化之一,通过自噬等清除异常聚集的蛋白对运动神经元(MN)蛋白稳态的维系和保护MN的功能具有重要作用,也是目前研究的前沿热点。HSPB8是小热休克家族中一员,HSPB8能够在MN中表达,并可能通过激活自噬等对MNs起保护作用,是个非常有潜力的治疗靶点,但是目前对HSPB8激活和调控机制尚不清楚。NF-κB通路参与众多重要生理病理过程,在体外实验中发现,它对神经元的分化和存活具有调控作用,研究HSPB8经NK-κB调控发挥MN保护作用将为ALS治疗提供新的理论依据。首先本研究基于公共数据库,挖掘分析了HSPB8在ALS患者及健康人群中的表达情况,评估出HSPB8作为ALS的差异表达基因,在ALS的预后及相关基因相互调控中有重要的作用。本项目还建立了ALS患者队列及罕见病患者iPSC库,并在此基础上开展相关科研工作,成功构建了ALS患者的iPSC,并进行了功能鉴定。此外我们使用前期报道的SOD1 G41D与SOD1 G41S两个家系,构建了SOD1 G41D和G41S动物模型,并于野生型及经典型SOD1 G93A小鼠模型进行对比,并进行了繁育、DNA测序及行为学检测,评估了SOD1 G41D和G41S突变的差异性。在SOD1突变动物模型中,HSPB8的表达显著下降,提示其可能具有保护作用。HSPB8通过上调NF-κB的激活,减轻了炎症反应,从而降低了细胞的毒性和损伤。该通路的调控对于神经元的存活至关重要。本研究为理解ALS的发病机制提供了新的视角,揭示了HSPB8在神经保护中的重要作用。更重要的是,该研究可能为ALS的治疗提供新的靶点,未来的干预研究可以考虑如何提高HSPB8的表达或活性,以改善患者的预后。
国内基金
海外基金